Autolus Therapeutics (AUTL) Free Cash Flow (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Free Cash Flow for 9 consecutive years, with -$66.4 million the latest figure, recorded in Q4 2025.

• Quarterly Free Cash Flow fell 35.46% year-over-year to -$66.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$302.6 million (down 32.52% YoY) and the FY2025 annual result came in at -$302.6 million, down 32.52% from the prior year.
• Free Cash Flow grew to -$66.4 million in Q4 2025 per AUTL's latest filing, from -$72.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for AUTL reached as high as -$10.7 million in Q4 2021 and fell as low as -$86.3 million in Q3 2024.
• A 5-year average of -$46.9 million and a median of -$41.4 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2021 — Free Cash Flow jumped 67.64% — and 2024, when it sank 107.09%.
• Year by year, Free Cash Flow stood at -$10.7 million in 2021, then plunged by 41.48% to -$15.2 million in 2022, then sank by 73.1% to -$26.3 million in 2023, then plunged by 86.42% to -$49.0 million in 2024, then slumped by 35.46% to -$66.4 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$66.4 million, -$72.3 million, and -$80.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.